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1Stratified medicine for estimating cardiovascular dis-ease (CVD) risk is a major responsibility of primary 
care.1 Health professionals use risk scores, such as ASSIGN, 
QRISK2, the Pooled Cohort Equations, and SCORE,2–4 to 
stratify and treat those at higher risk with statins, antihyper-
tensive medications, and lifestyle advice as required. The 
American Heart Association/American College of Cardiology 
task force recently altered its definition of a high-risk treat-
ment threshold in primary prevention from 20% 10-year 
risk to 7.5% 10-year risk.5 The National Institute of Health 
and Care Excellence in England and Wales also reduced the 
threshold, from 20% to 10% 10-year risk,6 whereas other 
national guidelines are still under revision.
Recently, cardiac biomarkers have become a major 
focus of attempts to improve CVD risk scores. Use of such 
biomarkers is attractive because they integrate signals from 
different pathophysiological pathways, including cardiac, 
vascular, and renal health. Data from several different cohort 
studies indicate that high-sensitivity troponins (hs-Tn) and 
N-terminal pro B-type natriuretic peptide (NT-proBNP)7–10 
are strong predictors of CVD risk. A recent editorial from 
the Bypass Angioplasty Revascularization Investigation 2 
Diabetes (BARI 2D) trial emphasises the importance of tro-
ponin data from cohort studies by suggesting that cardiac 
troponin values may become routinely used for risk stratifi-
cation across the spectrum of ischemic heart disease.11 More 
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recently, midregional pro adrenomedullin (MR-proADM) 
has also emerged as a biomarker of potential interest in CVD 
risk prediction.12–14 ADM, a natriuretic and diuretic peptide, is 
produced in human cardiac tissue (as well as adrenal glands, 
kidney tissues, and the vasculature) in response to mechanical 
stretch, much like natriuretic peptides. However, it is still not 
clear how much incremental information is gained by the use 
of multiple cardiac biomarkers in risk stratification, or whether 
they capture only overlapping risk information. Furthermore, 
although there is as yet no formal meta-analysis, the vast 
majority of cohort studies measuring cardiac biomarkers have 
focused on older and clinical trial cohorts, who will have sub-
stantially more prevalent and subclinical CVD than the young 
primary prevention groups CVD risk scores are intended for. 
Finally, in the context of national guidelines recommending 
lower thresholds of CVD risk for intervention with drugs to 
lower cholesterol or blood pressure, it is particularly impor-
tant to test whether any refinement of CVD risk scores using 
cardiac biomarkers improves the specificity of risk prediction, 
because specificity falls as thresholds are lowered.15
Given these uncertainties, we aimed to investigate the abil-
ity of these 3 cardiac biomarkers to predict CVD in 2 United 
Kingdom cohort studies. The 20-year follow-up British 
Regional Heart Study (BRHS Q20) is a cohort of older British 
men, and the MIDSPAN Family Study (MFS) is a British 
cohort of younger men and women. The hypothesis was that 
cardiac biomarkers would improve clinical decision making in 
risk prediction models, but that changing treatment thresholds 
would alter their utility.
Methods
British Regional Heart Study
The BRHS is a socioeconomically representative prospective study 
involving 7735 men, aged 40 to 59 years, of predominantly white 
European ethnicity (>99%), drawn from 1 general practice in each 
of 24 British towns, who were screened between 1978 and 1980.16 
In 1998 to 2000, all surviving men, then aged 60 to 79 years, were 
invited for a 20th year follow-up examination (Q20), on which the 
analyses presented here are based.8 Follow-up has been achieved for 
99% of the cohort. Data relating NT-proBNP to CVD in BRHS have 
been previously published using a different modeling approach, and 
without other cardiac biomarkers.8
In BRHS, CVD events were defined as a composite of CVD death 
(all of those who died with International Classification of Diseases 
Ninth Revision 401 to 459 listed on the death certificate as a primary 
or secondary cause) and nonfatal myocardial infarction or stroke. 
Evidence of nonfatal myocardial infarction or stroke was obtained 
by ad hoc reports from general practitioners supplemented by bi-
ennial reviews of the patients’ practice records (including hospital 
and clinic correspondence) through to the end of the study period. 
A nonfatal myocardial infarction was diagnosed according to World 
Health Organisation criteria. Nonfatal stroke events were those that 
produced a neurological deficit that was present for >24 hours.8
MIDSPAN Family Study
The MFS took place between March and December 1996. The study 
recruited adult sons and daughters of couples who had participated in 
the original Renfrew/Paisley prospective cohort study.17 In brief, off-
spring of the married couples identified within the Renfrew/Paisley 
cohort, aged 30 to 59 years and living locally, formed the eligible 
population (3202 offspring from 1767 families). In all, 1040 male and 
1298 female offsprings from 1477 families took part, and all partici-
pants were white18.
End points were identified by periodic review of the cohort us-
ing a national database: the Information Services Division National 
Health Service record linkage for Scotland. The Information Services 
Division–linked database contains information on Scotland’s morbidity 
records for acute specialty day case and inpatient discharges from hos-
pital (Scotland’s morbidity record 01) since January 1981. Death certifi-
cates were obtained from the National Health Service Central Register 
where the participants were flagged. For this study, the CVD end point 
was any event included in the national ASSIGN risk score definition 
of CVD: International Classification of Diseases Tenth Revision codes 
I20-25, G45, I60-69, as well as death from CVD (I00-I99), and OPCS4 
procedure codes L29.5, L31.1, K40-46, K49, and K75 (procedures 
comprising carotid endarterectomy, carotid angioplasty, coronary artery 
bypass graft, and percutaneous transluminal coronary angioplasty).
Biomarker Measurement
NT-proBNP and hsTnT were measured in plasma samples from 
both the studies on an automated clinically validated immunoassay 
analyzer (e411, Roche Diagnostics, Burgess Hill, United Kingdom) 
using the manufacturers’ calibrators and quality control reagents. 
MR-proADM was measured on an automated B.R.A.H.M.S Kryptor 
Compact plus (Thermo Fisher Scientific Hemel Hempstead, United 
Kingdom). The limit of detection was 5 pg/mL for NT-proBNP, 3 pg/
mL for hsTnT, and 0.05 nmol/L for MR-proADM. Quality control 
materials >2 levels for each biomarker ran between 4.4% and 7.7% 
between runs.
Statistics
From screening in 1998 to 2000 in the BRHS and 1996 in MFS, CVD 
events were based on follow-up to a first qualifying CVD event or 
censoring at a maximum 14.3 years of follow-up (median, 13.0 years) 
in BRHS and maximum 17.8 years of follow-up (median, 17.3 years) 
in MFS.
In both the studies, analyses were conducted for primary CVD 
events (defined as events occurring in the cohort after excluding those 
with previous CVD, either self-reported or occurring in previous sur-
veys, and those taking statin medication at baseline) as well as all 
CVD events (ie, without the above exclusions). As a post hoc analy-
sis, secondary CVD risk prediction was also tested in those with base-
line CVD in the BRHS, but not in MFS because of lower power. All 
available data were used in all models, leading to models with more 
risk factors having fewer observations because of missing covariates.
Standard crude analyses and Cox proportional hazard models were 
used. C-indices were derived using the somersd package (STATA) 
used for survival data.19 C-indices were calculated in BRHS using 
predictors broadly based on those included in QRISK2 (the risk 
score used by National Institute of Health and Care Excellence for 
the United Kingdom6), and in MFS using predictors broadly based 
on those included in ASSIGN (the risk score used in Scotland4). 
Increased concordance was tested on addition of combinations of 
cardiac biomarkers. Improved prediction was also tested using the 
net reclassification index for survival data using the nricens package 
(R) with 5000 bootstraps.20 To improve comparability of the cohorts 
while maximizing study power for this metric, follow-up times for 
both the studies were censored at 14 years (representing the maximum 
available whole year of follow-up time of BRHS). The categorical net 
reclassification index was calculated using binary risk thresholds for 
clinical treatments of 14% 14-year risk and 28% 14-year risk (which 
were taken to ≈10% 10-year risk and 20% 10-year risk frequently 
cited in clinical guidelines).6 All analyses were performed in STATA 
(version 13.1) and R (version 3.1.1).
Results
Baseline Data
In BRHS, 3757 of 4252 male participants had complete base-
line data for all 3 cardiac biomarkers (88.3%). At baseline 
across thirds of all 3 cardiac biomarkers, there was a trend for 
higher levels to be associated with higher risk demographic 
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and cardiometabolic characteristics, with the exception that 
NT-proBNP and hsTnT were inversely associated with total 
cholesterol. A CVD event occurred in 788 participants, and 
the event rate was 21.0 per 1000 patient-years in the full cohort 
and 16.6 per 1000 patient-years in those without baseline 
CVD or statin prescription. Those who experienced an inci-
dent CVD event generally had more adverse classical CVD 
risk factor characteristics (see online-only Data Supplement). 
In MFS, 2226 of 2338 participants had complete baseline 
data for all 3 cardiac biomarkers and consented to long-term 
follow-up (95.2%). Higher levels of NT-proBNP were associ-
ated with adverse risk factor characteristics (older age, chronic 
kidney disease, and higher baseline CVD prevalence) but also 
many protective characteristics (female sex, lower body mass 
index, enhanced lipid profile, and lower glucose/diabetes melli-
tus). In contrast, higher levels of hsTnT and MR-proADM were 
more consistently associated with adverse risk characteristics. 
In MFS, 195 experienced a CVD event, and the event rate was 
5.8 per 1000 patient-years in the full cohort with biomarker 
measurements and 5.3 per 1000 patient-years in those without 
baseline CVD or statin prescription. Those who experienced an 
incident CVD event generally had a more adverse classical CVD 
risk factor characteristics (see online-only Data Supplement).
Associations of Cardiac Biomarkers With  
CVD Risk
Across thirds of the biomarker distribution, elevated levels of 
all 3 cardiac biomarkers were associated with decreased event-
free survival during the follow-up time (Figure). In BRHS, 
1 SD increases in all 3 cardiac biomarkers because continu-
ous variables were associated with increased risk of all CVD 
in extensively adjusted models (Table 1). Of the 3 cardiac 
biomarkers, NT-proBNP was the most strongly associated 
with risk. After cross adjusting for all 3 cardiac biomarkers 
(through inclusion in the same model; Table 1 model 3), both 
NT-proBNP and hsTnT remained associated with CVD risk, 
but the association of MR-proADM with all CVD outcomes 
was attenuated to the null. These results were consistent when 
the model was restricted to those without previous CVD or 
statin prescription, although the strength of the associations 
was somewhat attenuated to the null in all models.
In MFS, both NT-proBNP and hsTnT were positively 
associated with risk of all CVD and primary CVD (Table 1). 
NT-proBNP and hsTnT were more weakly associated with 
all CVD outcomes than in BRHS, but there was little differ-
ence in the strength of hazard ratios between the 2 cohorts 
for primary CVD, although confidence intervals were wider 
in MFS reflecting lower power. Cross adjustment for all 3 car-
diac biomarkers in the same model attenuated results to the 
null, although both NT-proBNP and hsTnT retained a weak 
association with both all CVD and primary CVD (Table 1).
Prediction of CVD in Risk Score Models
In BRHS participants without baseline CVD or previous statin 
prescription, a risk score based on factors included in QRISK2 
yielded a C-index of 0.657 (Table 2). The c-index improved 
by 0.017 (P=0.005), 0.005 (P=0.28), and 0.005 (P=0.11) on 
addition of NT-proBNP, hsTnT, and MR-proADM, respec-
tively. There was no evidence that combinations of biomarkers 
improved discrimination beyond the improvement gained 
from the addition of NT-proBNP. Data were essentially 
unchanged when ASSIGN score risk factors were used as the 
baseline predictor model in BRHS, therefore, demonstrating 
consistency of the results by different modeling approaches. 
In an exploratory post hoc analysis testing risk prediction of 
secondary CVD, hsTnT particularly strongly improved the 
discrimination of secondary CVD events (see online-only 
Data Supplement). Investigating risk category reclassification 
in primary CVD using binary models, NT-proBNP improved 
risk classification of 5.9% (95% confidence interval, 2.8%–
9.2%) among cases (but not noncases) at a conservative 28% 
14-year threshold. In contrast, NT-proBNP improved classi-
fication among noncases (4.6%; 2.9%–6.3%; but not cases) 
at a more radical 14% 14-year threshold (Table 3). Similar 
trends were observed for hsTnT. There was no evidence that 
MR-proADM improved risk classification in any model.
In MFS participants without baseline CVD or previous 
statin prescription, a risk score based on risk factors included 
in ASSIGN (the risk score generally used in Scotland) yielded 
a C-index of 0.752 (Table 2). There was no evidence that 
individual or combined biomarkers improved discrimination. 
NT-proBNP improved risk classification only among cases at 
a 28% 14-year risk threshold by 4.7% (95% confidence inter-
val, 1.0%–9.2%), but not at a 14% 14-year risk threshold. 
NT-proBNP did not improve the classification of noncases 
in any model (Table 3). hsTnT slightly improved risk clas-
sification only among cases at the 28% 14-year threshold. 
MR-proADM did not improve risk classification in any model.
Discussion
In these 2 British cohort studies with a 23-year mean age dif-
ference and substantially different primary CVD event rates, 
the cardiac biomarker NT-proBNP only improved discrimina-
tion of CVD in the older BRHS cohort. Importantly, there was 
evidence that NT-proBNP and hsTnT improved classification 
of cases at a 28% 14-year risk threshold (theoretically result-
ing in more correct decisions to commence preventative treat-
ment), but only improved classification of noncases at a 14% 
14-year risk threshold (resulting in more correct decisions to 
not treat). As such, these biomarkers improved the sensitivity 
of risk prediction at the higher threshold, but improved speci-
ficity at the lower threshold. In contrast, MR-proADM was 
consistently a poor risk predictor of CVD. These data suggest 
that the clinical use (and health economics) of measuring these 
biomarkers in CVD risk stratification will depend on the risk 
threshold chosen for commencing preventative treatments, as 
well as characteristics of the screening population. These data 
are important to highlight in the context of ongoing changes 
to national guidelines for CVD risk scoring,5,6 particularly 
because the specificity of cardiovascular risk prediction falls 
as 10-year CVD risk thresholds are lowered.15
Recent mendelian randomization studies have shown that the 
active BNP hormone might protect against diabetes mellitus.21 
Data from the Prospective Comparison of ARNi With ACE-I to 
Determine Impact on Global Mortality and Morbidity in Heart 
Failure (PARADIGM-HF) trial of the LCZ696 drug suggest that 
a neprilysin inhibitor, which prevents degradation of circulat-
ing natriuretic hormones is efficacious in improving outcomes 
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and lowering blood pressure in the context of heart failure with 
reduced ejection fraction.22 As such, it is important to bear in 
mind that natriuretic peptides are physiologically protective hor-
mones, and slightly elevated NT-proBNP in young people may 
not always be reflective of pathology. However, in older people 
with more comorbidity, elevated levels of natriuretic peptides 
become a more consistent biomarker of pathophysiological pro-
cesses. In contrast to NT-proBNP, elevated troponin T seems to 
be a more consistent marker of characteristics that increase the 
risk of CVD in both the studies. Therefore characteristics of the 
Figure. Kaplan–Meier curves showing cardiovascular disease event-free survival by thirds of all 3 cardiac biomarkers in both British Regional 
Heart Study (BRHS) and MIDSPAN Family Study (MFS). Blue line represents the lowest tertile (t1), red line intermediate (t2), and green top 
tertile (t3). Cut points ranges for thirds are defined in the online-only Data Supplement. P values are for log-rank tests. hsTnT indicates high-
sensitivity troponin T; MR-proADM, midregional pro adrenomedullin; and NT-proBNP, N-terminal pro B-type natriuretic peptide.
Table 1.  Associations of Cardiac Biomarkers (Per SD Increase on Log Scale) With CVD During Maximum Follow-Up Time
Study/Events Variable
Model 1 Model 2 Model 3
n (n Events) HR (95% CI) P Value n (n Events) HR (95% CI) P Value n (n Events) HR (95% CI) P Value
BRHS all CVD 
events
NT-proBNP 3538 (736) 1.49 (1.38–1.62) <0.001 3319 (681) 1.46 (1.34–1.59) <0.001 3319 (681) 1.38 (1.26–1.51) <0.001
hsTnT 1.37 (1.27–1.47) <0.001 1.34 (1.24–1.45) <0.001 1.24 (1.14–1.34) <0.001
MR-proADM 1.17 (1.07–1.28) <0.001 1.16 (1.05–1.28) 0.003 0.98 (0.90–1.08) 0.70
BRHS primary* 
CVD
NT-proBNP 2884 (514) 1.41 (1.28–1.56) <0.001 2715 (475) 1.35 (1.21–1.50) <0.001 2715 (475) 1.30 (1.16–1.46) <0.001
hsTnT 1.26 (1.15–1.38) <0.001 1.23 (1.11–1.35) <0.001 1.16 (1.05–1.29) 0.004
MR-proADM 1.17 (1.05–1.32) 0.006 1.12 (0.99–1.26) 0.07 0.99 (0.88–1.11) 0.89
MFS all CVD NT-proBNP 1907 (154) 1.35 (1.15–1.60) <0.001 1746 (145) 1.27 (1.06–1.51) 0.008 1746 (145) 1.18 (0.99–1.42) 0.07
hsTnT 1.21 (1.09–1.33) <0.001 1.18 (1.06–1.31) 0.002 1.15 (1.02–1.29) 0.02
MR-proADM 1.23 (1.02–1.48) 0.027 1.17 (0.97–1.43) 0.11 1.11 (0.91–1.35) 0.30
MFS primary* 
CVD events
NT-proBNP 1878 (141) 1.43 (1.18–1.72) <0.001 1721 (135) 1.33 (1.09–1.62) 0.005 1721 (135) 1.24 (1.01–1.52) 0.04
hsTnT 1.22 (1.11–1.34) <0.001 1.20 (1.08–1.33) <0.001 1.17 (1.05–1.30) 0.005
MR-proADM 1.17 (0.97–1.42) 0.10 1.16 (0.95–1.41) 0.15 1.09 (0.89–1.33) 0.39
Model 1: adjusting for: age, sex, total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure, diastolic blood pressure, index of multiple deprivation 
(fifths), smoking (yes, no, and ex-smoker), diabetes mellitus, family history, chronic kidney disease, treated blood pressure, rheumatoid arthritis, previous CVD. Model 
2: additionally for: glucose, physical activity, forced expiratory volume in 1 s, alcohol use, and C-reactive protein. Model 3: additionally cross adjusted for N-terminal pro 
B-type natriuretic peptide (NT-proBNP), high-sensitivity troponin T (hsTnT), midregional pro adrenomedullin (MR-proADM); as relevant. BRHS indicates British Regional 
Heart Study; CI, confidence interval; CVD, cardiovascular disease; HR, hazard ratio; and MFS, MIDSPAN Family Study.
*Primary CVD excluding baseline CVD and baseline statin use.
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risk screening population may have some bearing on how car-
diac biomarkers perform as risk predictors.
The evidence of predictive ability of cardiac biomarkers 
in BRHS probably reflects (1) greater statistical power, (2) a 
greater burden of underlying subclinical disease in the older 
BRHS participants, and (3) a lower C-index in BRHS using 
classical risk factors compared with MFS. Cohorts that have 
hereto tested the use of cardiac biomarkers in CVD prediction 
Table 2. C-Index for the Prediction of Primary CVD (Among Those Not Taking Statin Medication at Baseline) by Cardiac 
Biomarkers in Addition to Risk Factors Based on Classical Risk Scores (QRISK2 and ASSIGN) During Maximum Follow-Up
Study Model n (n Events) Biomarker
C-Index Comparator Model
Classical Markers Classical+NT-proBNP Classical+hsTnT
BRHS primary CVD* 2811 (507) Reference score 0.657 0.674 0.662
2811 (507) NT-proBNP 0.674 (P=0.005) … 0.675 (P=0.007)
2811 (507) Troponin T 0.662 (P=0.28) 0.675 (P=0.80) …
2811 (507) MR-proADM 0.662 (P=0.11) 0.675 (P=0.72) 0.663 (P=0.24)
MFS primary CVD† 1890 (142) Reference score 0.752 0.763 0.758
1890 (142) NT-proBNP 0.763 (P=0.17) … 0.765 (P=0.25)
1890 (142) Troponin T 0.758 (P=0.28) 0.765 (P=0.55) …
1890 (142) MR-proADM 0.754 (P=0.65) 0.763 (P=0.66) 0.759 (P=0.74)
Abbreviations as in Table 1.
*Includes QRISK2-based variables (sex and ethnicity omitted)—age, index of multiple deprivation (fifths), systolic blood pressure, smoking (yes, no, and 
ex-smoker), diabetes mellitus, family history, chronic kidney disease (estimated glomerular filtration rate<60), atrial fibrillation, blood pressure treatment, 
rheumatoid arthritis, total:HDL cholesterol ratio, body mass index.
†Includes ASSIGN-based style variables—age, sex, index of multiple deprivation (continuous), family history, diabetes mellitus, rheumatoid arthritis, cigarettes 
smoked, systolic blood pressure, total cholesterol, HDL-cholesterol.
Table 3. Cardiac Biomarker 14-Year NRIs for Primary CVD Prediction in Those Not Taking Statins at Baseline
Study Model Biomarker
n (n Events) NRI (95% CI)
Group
Risk Categories
0% to 28%, >28%
Risk Categories
0% to 14%, >14%
BRHS primary CVD NT-proBNP 2811 (507) Cases 5.9% (2.8% to 9.2%) −0.9% (−4.2% to 2.3%)
Non-cases −1.0% (−2.2% to 0.1%) 4.6% (2.9% to 6.3%)
Overall 4.9% (1.4% to 8.3%) 3.7% (0.0% to 6.8%)
Troponin T 2811 (507) Cases 4.0% (1.8% to 6.5%) −2.0% (−4.6 to 0.8%)
Non-cases −0.4% (−1.3% to 0.6%) 2.1% (0.7% to 3.6%)
Overall 3.7% (1.1% to 6.3%) 0.2% (−2.9% to 3.3%)
MR-proADM 2811 (507) Cases 0.2% (−1.8% to 2.2%) 1.1% (−1.0% to 3.1%)
Non-cases −0.6% (−1.3% to 0.0%) 1.1% (0.1% to 2.2%)
Overall −0.4% (−2.5% to 1.7%) 2.2% (−0.2% to 4.5%)
All 3 biomarkers 2811 (507) Cases 5.3% (2.0% to 8.6%) −1.4% (−4.4% to 1.7%)
Non-cases −1.3% (−2.5% to −0.1%) 6.3% (4.5% to 7.9%)
Overall 4.0% (0.4% to 7.5%) 4.9% (1.1% to 8.5%)
MFS primary CVD NT-proBNP 1890 (107) Cases 4.7% (1.0% to 9.2%) −1.7% (−8.2% to 4.4%)
Non-cases −0.6% (−1.1% to −0.1%) −0.4% (−1.4% to 0.5%)
Overall 4.2% (0.5% to 8.6%) −2.2% (−8.6% to 4.2%)
Troponin T 1890 (107) Cases 2.6% (0.0% to 5.8%) −0.1% (−6.6% to 6.3%)
Non-cases −0.5% (−0.8% to −0.1%) 0.0% (−0.7% to 0.8%)
Overall 2.1% (−0.4% to 5.4%) −0.1% (−6.6% to 6.3%)
MR-proADM 1890 (107) Cases −1.7% (−4.4% to 0.0%) 3.9% (−0.9% to 9.2%)
Non-cases −0.2% (−0.5% to 0.1%) −0.4% (−1.0% to 0.3%)
Overall −1.9% (−4.6% to −0.1%) 3.5% (−1.3% to 8.8%)
All 3 biomarkers 1890 (107) Cases 6.2% (1.6% to 11.3%) 1.2% (−5.6% to 8.3%)
Non-cases −0.3% (−0.8% to 0.1%) −0.1% (−1.1% to 0.8%)
Overall 5.9% (1.6% to 11.3%) 1.1% (−5.9% to 8.3%)
Risk score prediction variables as per Table 2. Models approximate clinical thresholds for high risk at 10% 10-year risk (using 14% 14-year 
risk), and 20% 10-year risk (using 28% 14-year risk) across the 2 cohort. Abbreviations as in Table 1.
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have primarily comprised older participants at relatively high 
CVD risk, so the apparently low incremental discrimination 
gained from measuring cardiac biomarkers in the younger 
MFS is interesting. Indeed, our recent data from the Action 
in Diabetes and Vascular Disease: PreterAx and Diamicron 
MR Controlled Evaluation (ADVANCE) trial of patients with 
long-standing type 2 diabetes mellitus (a high-risk group) sug-
gested that both NT-proBNP and hsTnT were much stronger 
predictors than was seen in the studies reported here.10 Recent 
data from Multi-Ethnic Study of Atherosclerosis (MESA) 
suggests that ethnicity is unlikely to importantly modify the 
predictive ability of cardiac biomarkers.23 Therefore, general-
izability of cardiac biomarkers in CVD prediction is an ongo-
ing area of interest. Large ongoing cohort studies, including 
Generation Scotland, as well as future meta-analyses will 
address these issues.
Strengths and weaknesses of the study require consider-
ation. These are 2 large well-phenotyped prospective United 
Kingdom–based population studies, although small event 
numbers in MFS limited our power to observe small improve-
ments in discrimination and risk classification. Differences 
between the studies include not only age but also geographic 
location, sex composition, and definitions of CVD. The dif-
ferences in age at baseline allow a contrasting investigation 
of risk prediction, although BRHS only included male par-
ticipants. Measurement of multiple cardiac biomarkers in 
the studies allowed assessment of the use of combinations 
of biomarkers. NT-proBNP and hsTnT are already routinely 
measured by automated methods in many routine biochemis-
try laboratories, and thus clinical translation potential is high. 
Risk prediction models are based on self-calibration in the 
cohorts, rather than using published risk scores. This was a 
decision made to prevent overestimation of the clinical use of 
the cardiac biomarkers. The improvements we see for discrim-
ination using NT-proBNP are generally consistent with those 
seen for troponin I and BNP in a recent study in the Scottish 
Heart and Health Extended Cohort.9
Perspectives
The ability of NT-proBNP and hsTnT to correctly influence 
clinical treatment decisions to prevent CVD was influenced by 
the risk threshold chosen for commencing preventative treat-
ments, which is important in given recent changes to treatment 
thresholds in the guidelines. Meta-analysis and cost-effective-
ness modeling are required to assess the use of cardiac bio-
markers to aid risk prediction in a range of clinical settings.
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What Is New?
•	N-terminal pro B-type natriuretic peptide improved discrimination of fu-
ture cardiovascular disease in the British Regional Heart Study (BRHS) 
cohort but not in the MIDSPAN Family Study cohort. In a model approxi-
mating the clinical 20% 10-year cardiovascular disease risk treatment 
threshold, inclusion of N-terminal pro B-type natriuretic peptide and 
high-sensitivity troponin T in risk scores improved treatment decisions 
among cases in both the studies. In contrast, in a model approximating 
the 10% 10-year treatment threshold, inclusion of cardiac biomarkers in 
the risk score in BRHS resulted in improved treatment decisions among 
noncases only.
What Is Relevant?
•	The ability of cardiac biomarkers to improve treatment decisions was 
influenced by the risk threshold chosen for commencing preventative 
treatments. This is important against a background where guidelines are 
changing treatment thresholds in clinical practice toward interventions 
being indicated at lower risk.
Summary
Cardiac biomarkers still hold promise for cardiovascular disease 
risk prediction, but the changing landscape of the clinical risk pre-
diction guidelines to identify high-risk patients may limit the ability 
of cardiac biomarkers to improve risk score sensitivity.
Novelty and Significance







































































































































































































BMI  26.9 (3.5) 26.9 (3.6) 26.8 (3.92)  0.61 
IMD score  19.6  (14.4)  19.8  (14.4)  21.4  (15.3)  0.002 
SBP  144.2 (20.6) 149.2  (23.4) 153.4 (26.9)  <0.001
DBP  85.1 (9.9)  85.0  (10.9)  85.0  (12.6)  0.95 
TC  6.19 (1.07) 6.01 (1.05) 5.80 (1.07)  <0.001
HDL  1.32 (0.33)  1.32 (0.34)  1.32 (0.36)  0.97 
Glucose  6.01 (1.95) 5.99 (1.78) 6.09 (2.00)  0.37 
EGFR  74.9  (11.1) 73.3  (13.0) 68.8  (13.5)  <0.001

































Baseline CVD  79 (6.3%) 159 (13.1%) 358 (29.3%)  <0.001
Baseline DM  85 (6.7%)  78 (6.3%)  110 (8.8%)  0.031 
Family history  62 (5.0%) 60 (5.0%) 86 (7.2%)  0.028 
Statin use  47 (3.7%)  69 (5.6%)  130 (10.4%)  <0.001 































































BMI  26.4 (3.3) 26.9 (3.6) 27.3 (4.0)  <0.001
IMD score  19.3  (14.4)  20.2  (14.6)  21.3  (15.2)  0.004 
SBP  145.2  (22.6) 148.9  (23.0) 152.6  (25.9)  <0.001
DBP  85.0  (10.5)  84.9  (10.9)  85.3  (12.0)  0.66 
TC  6.06 (1.05) 6.00 (1.07) 5.95 (1.12)  0.023 
HDL  1.33 (0.34)  1.32 (0.34)  1.32 (0.35)  0.55 
Glucose  5.81 (1.24) 5.99 (1.92) 6.30 (2.38)  <0.001
EGFR  75.8  (11.6) 72.4  (11.1) 68.8  (14.5)  <0.001

































Baseline CVD  129 (10.4%) 200 (16.2%) 267 (22.1%)  <0.001
Baseline DM  59 (4.7%)  81 (6.4%)  133 (10.8%)  <0.001 
Family history  70 (5.7%) 60 (4.9%) 78 (6.5%)  0.23 
Statin use  78 (6.2%)  77 (6.1%)  91 (7.4%)  0.37 






























































BMI  25.9 (3.1) 26.9 (3.4) 27.9 (4.2)  <0.001
IMD score  18.7  (13.5)  19.7  (14.7)  22.6  (15.8)  <0.001 
SBP  145.8  (21.9) 149.9  (24.0) 151.2  (25.9)  <0.001
DBP  84.9  (10.2)  85.2  (11.1)  85.0  (12.2)  0.80 
TC  6.02 (1.06) 6.04 (1.06) 5.95 (1.11)  0.09 
HDL  1.37 (0.35)  1.31 (0.33)  1.28 (0.34)  <0.001 
Glucose  5.88 (1.53) 6.03 (2.07) 6.21 (2.09)  <0.001
EGFR  77.3  (11.5) 73.8  (11.1) 65.5  (12.9)  <0.001

































Baseline CVD  121 (9.5%) 191 (15.4%) 284 (24.4%)  <0.001
Baseline DM  79 (6.1%)  80 (6.3%)  114 (9.6%)  0.001 
Family history  64 (5.0%) 71 (5.7%) 73 (6.4%)  0.36 
Statin use  75 (5.8%)  80 (6.3%)  91 (7.6%)  0.16 












































Age  44.3 (5.7) 45.4 (6.1) 47.2 (6.2)  <0.001


















BMI  26.6 (4.1)  25.8 (4.5)  26.1 (5.1)  0.001 
IMD score  17.4 (13.6) 18.9 (14.5) 19.8 (14.7)  0.005 
SBP  127.8 (14.0)  126.1 (15.6)  127.1 (18.0)  0.13 
DBP  76.2 (10.6) 74.3 (10.7) 73.1 (12.3)  <0.001
TC  5.38 (0.93)  5.18 (0.93)  5.22 (1.01)  <0.001 
HDL  1.34 (0.32) 1.44 (0.37) 1.47 (0.38)  <0.001
Glucose  5.58 (1.98) 5.25 (1.33) 5.23 (1.30)  <0.001
eGFR  103.0 (64.2)  101.7 (25.5)  99.6 (27.1)  0.30 




































Baseline CVD  3 (0.4%)  3 (0.4%)  19 (2.6%)  <0.001 
Baseline DM  44 (5.8%) 27 (3.7%) 32 (4.4%)  0.14 
Family history  43 (5.7%)  44 (6.0%)  43 (6.0%)  0.95 
Statin use  5 (0.7%)  3 (0.4%)  6 (0.8%)  0.59 











































Age  44.8 (6.0) 46.1 (6.2) 47.4 (6.2) <0.001 


















BMI  25.7 (4.3)  26.6 (4.5)  27.2 (5.0)  <0.001 
IMD score  18.7 (14.4) 18.0 (14.0) 19.3 (14.4) 0.40 
SBP  124.8 (14.8)  129.5 (16.0)  131.2 (17.7)  <0.001 
DBP  72.9 (10.5)  76.4 (11.0)  77.6 (12.6)  <0.001 
TC  5.20 (0.94) 5.31 (0.99) 5.41 (0.97) <0.001 
HDL  1.44 (0.37)  1.40 (0.38)  1.37 (0.32)  0.002 
Glucose  5.26 (1.36) 5.37 (1.42) 5.62 (2.23) <0.001 
eGFR  102.9 (52.2)  101.2 (25.8)  97.4 (23.8)  0.07 




































Baseline CVD  13 (1.0%)  3 (0.7%)  9 (2.0%)  0.11 
Baseline DM  52 (4.0%) 25 (5.5%) 26 (5.9%) 0.15 
Family history  80 (6.0%)  25 (5.5%)  25 (5.6%)  0.88 
Statin use  6 (0.5%) 3 (0.7%) 5 (1.1%) 0.30 











































Age  44.2 (5.8) 45.4 (6.0) 47.3 (6.2)  <0.001


















BMI  24.8 (3.6)  26.0 (4.4)  27.8 (5.1)  <0.001 
IMD score  17.0 (13.3) 18.0 (14.4) 21.2 (14.9)  <0.001
SBP  123.6 (14.8)  126.3 (15.6)  131.3 (16.3)  <0.001 
DBP  72.2 (10.7) 74.3 (11.0) 77.3 (11.5)  <0.001
TC  5.10 (0.93)  5.27 (0.93)  5.42 (1.00)  <0.001 
HDL  1.47 (0.37) 1.40 (0.35) 1.37 (0.37)  <0.001
Glucose  5.18 (1.10) 5.28 (1.50) 5.61 (2.01)  <0.001
EGFR  104.1 (25.0)  103.0 (67.2)  97.1 (23.7)  0.0037 



































Baseline CVD  6 (0.8%) 7 (1.0%) 12 (1.6%)  0.26
Baseline DM  21 (2.7%)  25 (3.5%)  57 (7.8%)  <0.001 
Family history  49 (6.4%) 43 (5.9%) 38 (5.2%)  0.60
Statin use  3 (0.4%)  3 (0.4%)  8 (1.1%)  0.16 
















































Age (years)  68.2 (5.4)  70.5 (5.5) <0.001 45.3 (6.1) 49.0 (5.7)  <0.001






















BMI (kg/m2)  26.9 (3.7)  27.0 (3.7)  0.56  26.1 (4.5)  26.9 (5.0)  0.017 
IMD score*  20.0 (14.6)  21.4 (15.3)  0.014  18.4 (14.1)  22.2 (15.4)  <0.001 
SBP (mmHg)  147.7 (23.3)  153.3 (26.1) <0.001 126.3 (15.5) 134.6 (17.7) <0.001
DBP (mmHg)  84.9 (10.9)  85.6 (12.3) 0.12 74.1 (11.1) 79.2 (11.6) <0.001
Total‐c (mmol/L)  6.00 (1.08)  6.00 (1.08)  0.94  5.23 (0.95)  5.59 (1.00)  <0.001 
HDL‐c (mmol/L)  1.33 (0.34)  1.28 (0.33)  <0.001  1.43 (0.36)  1.30 (0.34)  <0.001 
Glucose (mmol/L)  5.95 (1.70)  6.34 (2.53)  <0.001  5.30 (1.37)  5.97 (2.95)  <0.001 
eGFR  73.1 (12.6)  70.0 (13.4) <0.001 101.6 (44.7) 100.4 (23.5) 0.71











































Baseline CVD  378 (13.0%)  218 (28.0%)  <0.001  10 (0.5%)  15 (7.7%)  <0.001 
Baseline DM  187 (6.3%)  86 (10.9%)  <0.001  83 (4.1%)  20 (10.4%)  <0.001 
Baseline RA  7 (0.2%)  3 (0.4%) 0.48 6 (0.3%) 1 (0.5%)  0.61
Family history CVD  150 (5.5%)  48 (6.3%)  0.41  115 (5.7%)  15 (7.7%)  0.25 
Statin use  172 (5.8%)  74 (9.4%)  <0.001  10 (0.5%)  4 (2.1%)  0.009 































































Study model N (n 
events) Biomarker C-index  comparator model 







2936 (523) Reference score 0.650 0.667 0.654 
 2936 (523) NT-proBNP 0.667 (p=0.007) - 
0.667 
(p=0.01) 
 2936 (523) Troponin T 0.654 (p=0.33) 
0.667 
(p=0.97) - 









Reference score 0.752 0.763 0.758 
 1890 (142) NT-proBNP 0.763 (p=0.17) - 
0.765 
(p=0.25) 
 1890 (142) Troponin T 0.758 (p=0.28) 
0.765 
(p=0.55) - 












Study model N (n 
events) Biomarker C-index  comparator model 








554 (204) Reference score 0.613 0.639 0.660 
 554 (204) NT-proBNP 0.639 (p=0.036) - 
0.665 
(p=0.17) 
 554 (204) Troponin T 0.660 (p=0.008) 
0.665 
(p=0.079) - 
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